期刊
CURRENT TOPICS IN MEDICINAL CHEMISTRY
卷 16, 期 4, 页码 415-426出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026615666150813145629
关键词
Class I; Class II; Class III; HDAC; HDAC1; HDAC6; Selective histone deacetylase inhibitors
资金
- National Natural Science Foundation [21172220, 21472191]
- Joint Fund of NSFC-Guangdong Province [U1401225]
HDAC inhibitors (HDACIs), which can be used to kill cancer cells through inhibiting histone deacetylase activity or altering the structure of chromatin, have emerged as efficacious agents in the treatment of cancer. With SAHA, FK228, belinostat and panobinostat approved by the FDA, displaying satisfying activity in both haematological and solid tumors of various tissues, efforts to create selective HDACIs have been attracted attention over the past several years. Herein, we mainly review the progress of selective HDAC inhibitors including class-selective and isoform-selective HDAC inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据